A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.
Ryan P Bennett, Courtney L Finch, Elena N Postnikova, Ryan A Stewart, Yingyun Cai, Shuiqing Yu, Janie Liang, Julie Dyall, Jason D Salter, Harold C Smith, Jens H Kuhn
Author Information
Ryan P Bennett: OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA. ORCID
Courtney L Finch: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Elena N Postnikova: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Ryan A Stewart: OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA.
Yingyun Cai: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Shuiqing Yu: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Janie Liang: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Julie Dyall: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Jason D Salter: OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA. ORCID
Harold C Smith: OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA. ORCID
Jens H Kuhn: NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA. ORCID
Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody-based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane. Using this assay, we screened nearly 3000 small molecules and identified several molecules with the desired inhibitory properties. In secondary assays, one identified compound, sangivamycin, inhibited not only Ebola viral infectivity but also that of other viruses. This finding indicates that it is possible for this new VP40-based screening method to identify highly potent MCMs against Ebola virus and its relatives.
